Cargando…

Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief

The 2009 “swine flu” pandemic outbreak demonstrated the limiting capacity for egg-based vaccines with respect to global vaccine supply within a timely fashion. New vaccine platforms that efficiently can quench pandemic influenza emergences are urgently needed. Since 2009, there has been a profound d...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersen, Tor Kristian, Bodin, Johanna, Oftung, Fredrik, Bogen, Bjarne, Mjaaland, Siri, Grødeland, Gunnveig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531196/
https://www.ncbi.nlm.nih.gov/pubmed/34691056
http://dx.doi.org/10.3389/fimmu.2021.747032
_version_ 1784586799924903936
author Andersen, Tor Kristian
Bodin, Johanna
Oftung, Fredrik
Bogen, Bjarne
Mjaaland, Siri
Grødeland, Gunnveig
author_facet Andersen, Tor Kristian
Bodin, Johanna
Oftung, Fredrik
Bogen, Bjarne
Mjaaland, Siri
Grødeland, Gunnveig
author_sort Andersen, Tor Kristian
collection PubMed
description The 2009 “swine flu” pandemic outbreak demonstrated the limiting capacity for egg-based vaccines with respect to global vaccine supply within a timely fashion. New vaccine platforms that efficiently can quench pandemic influenza emergences are urgently needed. Since 2009, there has been a profound development of new vaccine platform technologies with respect to prophylactic use in the population, including DNA vaccines. These vaccines are particularly well suited for global pandemic responses as the DNA format is temperature stable and the production process is cheap and rapid. Here, we show that by targeting influenza antigens directly to antigen presenting cells (APC), DNA vaccine efficacy equals that of conventional technologies. A single dose of naked DNA encoding hemagglutinin (HA) from influenza/A/California/2009 (H1N1), linked to a targeting moiety directing the vaccine to major histocompatibility complex class II (MHCII) molecules, raised similar humoral immune responses as the adjuvanted split virion vaccine Pandemrix, widely administered in the 2009 pandemic. Both vaccine formats rapidly induced serum antibodies that could protect mice already 8 days after a single immunization, in contrast to the slower kinetics of a seasonal trivalent inactivated influenza vaccine (TIV). Importantly, the DNA vaccine also elicited cytotoxic T-cell responses that reduced morbidity after vaccination, in contrast to very limited T-cell responses seen after immunization with Pandemrix and TIV. These data demonstrate that DNA vaccines has the potential as a single dose platform vaccine, with rapid protective effects without the need for adjuvant, and confirms the relevance of naked DNA vaccines as candidates for pandemic preparedness.
format Online
Article
Text
id pubmed-8531196
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85311962021-10-23 Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief Andersen, Tor Kristian Bodin, Johanna Oftung, Fredrik Bogen, Bjarne Mjaaland, Siri Grødeland, Gunnveig Front Immunol Immunology The 2009 “swine flu” pandemic outbreak demonstrated the limiting capacity for egg-based vaccines with respect to global vaccine supply within a timely fashion. New vaccine platforms that efficiently can quench pandemic influenza emergences are urgently needed. Since 2009, there has been a profound development of new vaccine platform technologies with respect to prophylactic use in the population, including DNA vaccines. These vaccines are particularly well suited for global pandemic responses as the DNA format is temperature stable and the production process is cheap and rapid. Here, we show that by targeting influenza antigens directly to antigen presenting cells (APC), DNA vaccine efficacy equals that of conventional technologies. A single dose of naked DNA encoding hemagglutinin (HA) from influenza/A/California/2009 (H1N1), linked to a targeting moiety directing the vaccine to major histocompatibility complex class II (MHCII) molecules, raised similar humoral immune responses as the adjuvanted split virion vaccine Pandemrix, widely administered in the 2009 pandemic. Both vaccine formats rapidly induced serum antibodies that could protect mice already 8 days after a single immunization, in contrast to the slower kinetics of a seasonal trivalent inactivated influenza vaccine (TIV). Importantly, the DNA vaccine also elicited cytotoxic T-cell responses that reduced morbidity after vaccination, in contrast to very limited T-cell responses seen after immunization with Pandemrix and TIV. These data demonstrate that DNA vaccines has the potential as a single dose platform vaccine, with rapid protective effects without the need for adjuvant, and confirms the relevance of naked DNA vaccines as candidates for pandemic preparedness. Frontiers Media S.A. 2021-10-08 /pmc/articles/PMC8531196/ /pubmed/34691056 http://dx.doi.org/10.3389/fimmu.2021.747032 Text en Copyright © 2021 Andersen, Bodin, Oftung, Bogen, Mjaaland and Grødeland https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Andersen, Tor Kristian
Bodin, Johanna
Oftung, Fredrik
Bogen, Bjarne
Mjaaland, Siri
Grødeland, Gunnveig
Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
title Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
title_full Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
title_fullStr Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
title_full_unstemmed Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
title_short Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
title_sort pandemic preparedness against influenza: dna vaccine for rapid relief
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531196/
https://www.ncbi.nlm.nih.gov/pubmed/34691056
http://dx.doi.org/10.3389/fimmu.2021.747032
work_keys_str_mv AT andersentorkristian pandemicpreparednessagainstinfluenzadnavaccineforrapidrelief
AT bodinjohanna pandemicpreparednessagainstinfluenzadnavaccineforrapidrelief
AT oftungfredrik pandemicpreparednessagainstinfluenzadnavaccineforrapidrelief
AT bogenbjarne pandemicpreparednessagainstinfluenzadnavaccineforrapidrelief
AT mjaalandsiri pandemicpreparednessagainstinfluenzadnavaccineforrapidrelief
AT grødelandgunnveig pandemicpreparednessagainstinfluenzadnavaccineforrapidrelief